No Data
Express News | BioXcel Therapeutics Presents New Data From Serenity at-Home Phase 3 Trial for Agitation Associated With Bipolar Disorders or Schizophrenia at 2026 Ascp Annual Meeting
BioXcel Therapeutics Presents New Data From SERENITY At-Home Phase 3 Trial for Agitation Associated With Bipolar Disorders or Schizophrenia at 2026 ASCP Annual Meeting
Earnings Scheduled For May 15, 2026
BioXcel Therapeutics | 8-K: BioXcel Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results
BioXcel Therapeutics GAAP EPS of -$0.54 Misses by $0.06, Revenue of $0.21M Misses by $0.17M
BioXcel Therapeutics | 10-Q: Quarterly report